Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: Dig Dis Sci. 2018 Jul 13;63(11):3067–3073. doi: 10.1007/s10620-018-5202-5

Figure 1.

Figure 1.

Distribution of serum adalimumab concentrations during maintenance therapy based on biochemical, endoscopic or histologic remission in patients with Crohn’s disease (A) and ulcerative colitis (B). Box plots (5–95%) show the median (solid line within box), interquartile range (upper and lower box boundaries), standard deviation (whiskers) and outliers (black dot).